


(A)

	c-MET exon	Protein domain	c-MET mutation	Tumor tissue
Extracellular domain	Exon 2 (58.1%)	Sema domain	A82V (N = 2)	P/M
			E91K (N = 1)	P
			P97S (N = 1)	M
			D100N (N = 1)	M
			Q142fs (N = 1)	P
			D270N (N = 1)	M
			M292I (N = 1)	M
			P351L (N = 1)	M
			N375S (N = 24)	P/M
			N381fs (N = 2)	M
			Y390fs (N = 1)	M
Intracellular domain	Exon 10 (1.6%)	IPT domain	R784K (N = 1)	M
	Exon 11 (14.5%)	IPT domain	C800Y (N = 1)	P
			S805F (N = 2)	P/M
			Q808* (N = 2)	P
			A819V (N = 1)	P
			G825R (N = 1)	P
			L827F (N = 1)	M
			L833F (N = 1)	P
	Exon 14 (9.6%)	Juxta-membrane domain	V969I (N = 1)	P
			R970C (N = 1)	M
			D972N (N = 1)	P
			A973V (N = 1)	M
			S988N (N = 1)	P
	Exon 15 (8.1%)	Kinase domain	T993A (N = 1)	P
			H1079Y (N = 1)	P
			E1082K (N = 1)	M
			G1085R (N = 1)	M
			G1085E (N = 1)	M
	Exon 16 (8.1%)	Kinase domain	R1086K (N = 1)	P
			G1087E (N = 1)	M
			H1088Y (N = 1)	P
			H1094Y (N = 1)	M
			T1096I (N = 1)	P
			C1107Y (N = 1)	M



Supplementary Figure S2. *MET* mutational patterns and overall survival. **(A)** All variants of *MET* mutations were analyzed from 112 surgical samples of advanced endometrial cancer, including 81 primary tumors (P) and 31 metastatic tissues (M). **(B)** The relationship between *MET* mutational patterns and overall survival.